Benzinga · Aug 26, 2026
UBS Upgrades argenx to Buy, Raises Price Target to $1400
UBS analyst Xian Deng upgrades argenx (NASDAQ:ARGX) from Neutral to Buy and raises the price target from $960 to $1400.
AR
NYSE · ARGX
argenx SE
Healthcare · Biotechnology
$1,023.21
Down-$35.69 (-3.37%)
Updated Aug 30, 2026, 7:09 AM
SID Score
6.3/10
Composite research score
Smart Money
60/100
Neutral
- Market cap
- 47.46B
- P/E ratio
- 42.26
- Dividend yield
- 0.00%
- 52-week range
- $661.85 – $1,061.57
- Volume
- 175.52K
- Avg. volume
- 347.54K
Price performance
ARGX price history
1M range · 20 trading sessions · Daily adjusted prices
ARGX closed at $1,023.21 after 20 trading sessions, up 23.16% for the selected period.
- Last close
- $1,023.21
- Period change
- +23.16%
- Period low
- $830.79
- Period high
- $1,058.90
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $1,049.87 | $1,053.00 | $1,018.60 | $1,023.21 | 175.52K |
| Aug 27, 2026 | $1,053.47 | $1,061.57 | $1,044.76 | $1,058.90 | 322.52K |
| Aug 26, 2026 | $1,033.83 | $1,057.91 | $1,032.85 | $1,047.10 | 362.1K |
| Aug 25, 2026 | $1,020.29 | $1,030.3599 | $1,013.75 | $1,019.49 | 142.23K |
| Aug 24, 2026 | $1,023.76 | $1,031.18 | $1,001.505 | $1,011.11 | 318.43K |
| Aug 21, 2026 | $1,034.98 | $1,058.69 | $1,029.46 | $1,039.78 | 377.3K |
| Aug 20, 2026 | $1,019.16 | $1,039.30 | $1,018.98 | $1,038.12 | 258.3K |
| Aug 19, 2026 | $1,020.51 | $1,035.09 | $1,011.95 | $1,032.86 | 390.89K |
| Aug 18, 2026 | $988.49 | $1,009.745 | $980.45 | $992.99 | 333.94K |
| Aug 17, 2026 | $927.33 | $1,002.1566 | $925.62 | $987.84 | 684.01K |
| Aug 14, 2026 | $845.36 | $852.08 | $837.42 | $851.29 | 278.71K |
| Aug 13, 2026 | $878.94 | $878.94 | $856.29 | $856.94 | 171.35K |
| Aug 12, 2026 | $858.54 | $881.4399 | $857.52 | $876.00 | 172.62K |
| Aug 11, 2026 | $873.91 | $876.38 | $855.79 | $864.74 | 476.35K |
| Aug 10, 2026 | $867.55 | $887.41 | $860.00 | $866.11 | 361.41K |
| Aug 7, 2026 | $890.47 | $894.03 | $862.60 | $865.04 | 250.02K |
| Aug 6, 2026 | $875.66 | $884.75 | $863.88 | $875.30 | 227.1K |
| Aug 5, 2026 | $868.63 | $878.72 | $855.14 | $867.94 | 358.8K |
| Aug 4, 2026 | $840.76 | $850.355 | $832.71 | $844.50 | 264.38K |
| Aug 3, 2026 | $838.99 | $841.89 | $826.445 | $830.79 | 257.86K |
Latest ARGX news
The latest Smart Investors Daily articles mentioning ARGX.
Stock researchCompany · Overview
ARGX research
Overview
Company profile and research snapshot.
Company profile
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $967.36
- Implied upside
- —
- Analysts
- 9
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 13, 2026 | ROTHSCHILD & CO REDBURN | Buy | — |
| Jul 12, 2026 | TD COWEN | Buy | — |
| Jul 12, 2026 | DAY BY DAY | Buy | — |
| Jul 1, 2026 | KBC SECURITIES | Buy | — |
| Jun 24, 2026 | H.C. WAINWRIGHT & CO., LLC | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 26, 2026
Wells Fargo Maintains Overweight on argenx, Raises Price Target to $1415
Wells Fargo analyst Derek Archila maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $1350 to $1415.
SeekingAlpha · Aug 20, 2026
argenx SE (ARGX) Discusses Positive Phase 3 ALKIVIA Trial Results for VYVGART Hytrulo in Autoimmune Myositis - Slideshow
2026-08-20. The following slide deck was published by argenx SE in conjunction with this event.
Benzinga · Aug 18, 2026
Truist Securities Maintains Buy on argenx, Raises Price Target to $1095
Truist Securities analyst Danielle Brill maintains argenx (NASDAQ:ARGX) with a Buy and raises the price target from $1030 to $1095.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
